G Medical Innovations (ASX:GMV) has engaged a New York based underwriter to assist in the processes towards a US public offering via the NASDAQ stock exchange.
The company will remain listed on the ASX and will proceed with the submission of the F-1 Registration Statement towards a US listing within the next 4 to 5 months.
The listing is subject to satisfaction of all legal and regulatory requirements with NASDAQ, US Securities and Exchange Commission (SEC) and ASX, as well as any shareholder approvals that may be required under the ASX Listing Rules.
The amount of capital to be raised will be determined closer to the proposed offering.
G Medical’s key product, Prizma, is a smartphone case that transforms any smartphone into a medical monitoring device.
It is a comprehensive solution that monitors a full range of vital signs and biometric parameters, continuously collecting, consolidating and analysing medical data to detect trends over time.
Prizma allows users to store their medical data in the cloud and share it with third parties including professionals and family.
READ: G Medical Innovations a leading gainer on news of proposed Hong Kong listing of Chinese subsidiary
The company recently revealed its intention to list its Chinese subsidiary on the main board of the Hong Kong Stock Exchange.
G Medical has engaged global investment bank, UOB Kay Hian (Hong Kong) Ltd, as advisers for the listing of Guangzhou Yimei Innovative Medical Science and Technology Co Ltd (GYIMSTC).
GYIMSTC oversees China-based manufacturing for G Medical, ensures all local certifications are met and has worked to build a strong relationship with the China Food and Drug Administration (CFDA).
